Scarica l'app Stockscreener
44.06
0.92%
0.40
Precedente Chiudi:
$43.66
Aprire:
$43.8
Volume 24 ore:
807.45K
Relative Volume:
1.03
Capitalizzazione di mercato:
$3.40B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-16.08
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
-2.11%
1M Prestazione:
+11.04%
6M Prestazione:
+34.33%
1 anno Prestazione:
+11.69%
Intervallo 1D:
$43.28
$44.57
Intervallo di 1 settimana:
$42.89
$46.60
Portata 52W:
$26.74
$46.60
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
44.06 | 3.37B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation - Nasdaq
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE - GuruFocus
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline - MSN
Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares - Investing.com
Xenon Pharmaceuticals unveils promising long-term epilepsy treatment data - MSN
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Xenon Pharmaceuticals issues equity inducement grants to new employees - MSN
New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week HighHere's What Happened - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC's 3rd Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC’s 3rd Largest Position - Defense World
Evaluating Xenon Pharmaceuticals (XENE)’s Valuation After Its Recent Share Price Rebound - Sahm
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD By Investing.com - Investing.com India
XENE Unveils Promising Data on Epilepsy Treatment Advances - GuruFocus
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD - Investing.com
Xenon Pharmaceuticals Unveils Promising Long-Term Epilepsy Treatment Data - TipRanks
Xenon Pharmaceuticals Reports Significant Long-Term Efficacy of Azetukalner in Epilepsy at AES 2025 - Quiver Quantitative
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 - The Manila Times
Saturn V Capital Management LP Boosts Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How Xenon Pharmaceuticals Inc. stock performs in rate cut cyclesJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares By Investing.com - Investing.com Canada
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares - Investing.com
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? - sharewise.com
Xenon Pharmaceuticals to Host Webinar on Epilepsy Data and Commercialization Plans - TipRanks
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 - GlobeNewswire
JPMorgan Chase & Co. Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Loomis Sayles & Co. L P Sells 15,846 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
American Century Companies Inc. Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Expands 2025 Equity Incentive Plan - TipRanks
(XENE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Ameritas Investment Partners Inc. Acquires Shares of 7,758 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Franklin Resources Inc. Purchases 175,346 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Geode Capital Management LLC Purchases 900,746 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention - Sahm
Xenon Reports Second Quarter 2025 Financial Results & Business Update - ADVFN
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD - Investing.com
Intech Investment Management LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Dec 08 '25 |
Sale |
45.73 |
10,830 |
495,207 |
6,000 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):